Benitec Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Benitec Biopharma (BNTC).

Price Target Range — 12 Quarters

Analyst Consensus — 11 Analysts

3S.Buy

8Buy

Consensus RatingOutperform# Analysts11Avg. Consensus PT$23Upside to Avg. PT+90.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 15, 2026	Wedbush	Yun Zhong	PT Raise	Outperform	$16→$17
Jul 28, 2026	Wedbush	Yun Zhong	Initiate	Outperform	$16
May 12, 2026	Evercore ISI Group	Cory Kasimov	Initiate	Outperform	$25
Mar 9, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$32
Nov 24, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$35→$32
Nov 4, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$28→$35
Nov 4, 2025	Citizens	Silvan Tuerkcan	PT Raise	Market Outperform	$20→$22
Sep 24, 2025	JMP Securities	Silvan Tuerkcan	Maintained	Market Outperform	$20
Sep 16, 2025	Oppenheimer	Andreas Argyrides	PT Cut	Outperform	$35→$29
May 19, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$28
May 15, 2025	JMP Securities	Silvan Tuerkcan	Maintained	Market Outperform	$20
Apr 10, 2025	JMP Securities	Silvan Tuerkcan	PT Raise	Market Outperform	$18→$20
Mar 24, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$28
Mar 18, 2025	Citizens Capital Markets	Silvan Tuerkcan	Maintained	Market Outperform	$18
Feb 21, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$28
Dec 13, 2024	Baird	Brian Skorney	Initiate	Outperform	$30
Dec 3, 2024	Guggenheim	Debjit Chattopadhyay	Maintained	Buy	$17
Oct 16, 2024	Oppenheimer	Andreas Argyrides	Initiate	Outperform	$35
Oct 14, 2024	JMP Securities	Silvan Tuerkcan	PT Raise	Market Outperform	$16→$18
Sep 30, 2024	JMP Securities	Silvan Tuerkcan	Maintained	Market Outperform	$16

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17

Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $16 to $17.

Benzinga Newsdesk

This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings page. Analysts have positive views on FTH stock.

Avi Kapoor

PRO
Wedbush Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $16

Wedbush analyst Yun Zhong initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $16.

Benzinga Newsdesk

PRO
Evercore ISI Group Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $25

Evercore ISI Group analyst Cory Kasimov initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $25.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Benitec Biopharma, Maintains $32 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Benitec Biopharma (NASDAQ:BNTC) with a Buy and maintains $32 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Benitec Biopharma, Lowers Price Target to $32

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Benitec Biopharma (NASDAQ:BNTC) with a Buy and lowers the price target from $35 to $32.

Benzinga Newsdesk

Benitec Biopharma Inc

Benitec Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17

This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PRO
Wedbush Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $16

PRO
Evercore ISI Group Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $25

PRO
HC Wainwright & Co. Reiterates Buy on Benitec Biopharma, Maintains $32 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Benitec Biopharma, Lowers Price Target to $32

People Also Watch

People Also Watch

Benitec Biopharma Inc

Benitec Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17

This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PROWedbush Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $16

PROEvercore ISI Group Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $25

PROHC Wainwright & Co. Reiterates Buy on Benitec Biopharma, Maintains $32 Price Target

PROHC Wainwright & Co. Maintains Buy on Benitec Biopharma, Lowers Price Target to $32

People Also Watch

People Also Watch

PRO
Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17

PRO
Wedbush Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $16

PRO
Evercore ISI Group Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $25

PRO
HC Wainwright & Co. Reiterates Buy on Benitec Biopharma, Maintains $32 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Benitec Biopharma, Lowers Price Target to $32